Avery Peter, Barzilai Nir, Benetos Athanase, Bilianou Helen, Capri Miriam, Caruso Calogero, Franceschi Claudio, Katsiki Niki, Mikhailidis Dimitri P, Panotopoulos George, Sikora Ewa, Tzanetakou Irene P, Kolovou Genovefa
Onassis Cardiac Surgery Center 356 Sygrou Ave 176 74 Athens Greece.
Curr Vasc Pharmacol. 2014;12(5):659-61. doi: 10.2174/1570161111666131219101226.
In May 2012, a group of scientists and clinicians met in Athens (Greece) to consider the relevance of ageing, longevity, exceptional longevity and related genetic and non genetic markers. During this meeting, we firstly reviewed recent epidemiological and clinical studies on ageing, longevity and exceptional longevity, briefly analyzed the ageing theories and discussed successful and unsuccessful ageing also taking into account the evolutionary perspective. Secondly, we considered the three phenotypes based on the definition of ageing, longevity and exceptional longevity and the associated biomarkers. Third, we discussed proposed treatments suitable to counteract or slow down ageing. Finally, this panel produced a consensus statement to highlight the importance of ageing, longevity and exceptional longevity, since this is a rapidly increasing phenotype worldwide. We acknowledge that not all experts in this field may completely agree with this statement.
2012年5月,一群科学家和临床医生在雅典(希腊)会面,探讨衰老、长寿、超长寿命以及相关遗传和非遗传标志物的相关性。在这次会议期间,我们首先回顾了近期关于衰老、长寿和超长寿命的流行病学和临床研究,简要分析了衰老理论,并从进化的角度讨论了成功衰老和非成功衰老。其次,我们根据衰老、长寿和超长寿命的定义以及相关生物标志物考虑了三种表型。第三,我们讨论了拟用于对抗或延缓衰老的治疗方法。最后,该小组发表了一份共识声明,以强调衰老、长寿和超长寿命的重要性,因为这是一种在全球范围内迅速增加的表型。我们承认该领域的并非所有专家都可能完全同意这一声明。